Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Ritchie

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Thrombosis and Haemostasis|March 23, 2018
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort StudySam Schulman, Peter L Gross, Bruce Ritchie, et al.
Frontiers in Immunology|February 20, 2019
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary ImmunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.
Frontiers in Immunology|January 6, 2023
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig<sup>®</sup>]) in the treatment of patients with primary immunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.
Lancet (London, England)|January 24, 2006
Clinical perspectives of emerging pathogens in bleeding disordersChristopher A Ludlam, William G Powderly, Samuel Bozzette, et al.
European Journal of Haematology|March 31, 2016
The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac diseaseLalit Saini, Joseph Brandwein, Robert Turner, et al.
Medrxiv : the Preprint Server for Health Sciences|June 15, 2022
α2,6-Sialylation is Upregulated in Severe COVID-19 Implicating the Complement CascadeRui Qin, Emma Kurz, Shuhui Chen, et al.
ACS Infectious Diseases|October 11, 2022
α2,6-Sialylation Is Upregulated in Severe COVID-19, Implicating the Complement CascadeRui Qin, Emma Kurz, Shuhui Chen, et al.
Clinical and Experimental Immunology|October 8, 2022
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficienciesRoger H Kobayashi, Jiří Litzman, Isaac Melamed, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2009
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacksTimothy J Craig, Robyn J Levy, Richard L Wasserman, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 3, 2010
Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacksJonathan A Bernstein, Bruce Ritchie, Robyn J Levy, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Thrombosis and Haemostasis|March 23, 2018
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort StudySam Schulman, Peter L Gross, Bruce Ritchie, et al.
Frontiers in Immunology|February 20, 2019
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary ImmunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.
Frontiers in Immunology|January 6, 2023
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig<sup>®</sup>]) in the treatment of patients with primary immunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.
Lancet (London, England)|January 24, 2006
Clinical perspectives of emerging pathogens in bleeding disordersChristopher A Ludlam, William G Powderly, Samuel Bozzette, et al.
European Journal of Haematology|March 31, 2016
The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac diseaseLalit Saini, Joseph Brandwein, Robert Turner, et al.
Medrxiv : the Preprint Server for Health Sciences|June 15, 2022
α2,6-Sialylation is Upregulated in Severe COVID-19 Implicating the Complement CascadeRui Qin, Emma Kurz, Shuhui Chen, et al.
ACS Infectious Diseases|October 11, 2022
α2,6-Sialylation Is Upregulated in Severe COVID-19, Implicating the Complement CascadeRui Qin, Emma Kurz, Shuhui Chen, et al.
Clinical and Experimental Immunology|October 8, 2022
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficienciesRoger H Kobayashi, Jiří Litzman, Isaac Melamed, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2009
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacksTimothy J Craig, Robyn J Levy, Richard L Wasserman, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 3, 2010
Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacksJonathan A Bernstein, Bruce Ritchie, Robyn J Levy, et al.
Pageof 7